Quick Comparison
| Testagen | Thymosin Beta-4 | |
|---|---|---|
| Half-Life | Approximately 30 minutes (acute pharmacology); proposed gene-expression effects outlast plasma exposure | 1-2 hours |
| Typical Dosage | Oral (capsule): 100-200 mg once daily for 10-30 day cycles, repeated 2-3 times per year. Subcutaneous injection: 1-5 mg per dose, alternate days for 10-20 day cycles. Cycling protocol consistent with the Khavinson family. | Loading: 750 mcg-2 mg subcutaneous two or three times weekly for 2-4 weeks. Maintenance: 750 mcg-2 mg subcutaneous once or twice weekly. Some protocols use higher loading doses for acute injuries. |
| Administration | Oral capsule or subcutaneous injection (cycled) | Subcutaneous injection |
| Research Papers | 2 papers | 30 papers |
| Categories |
Mechanism of Action
Testagen
Testagen is a short Khavinson tetrapeptide (Lys-Glu-Asp-Gly) positioned as the male reproductive and prostate tissue bioregulator within the wider Khavinson peptide family. The proposed mechanism is consistent with the family-wide model: short peptides interact with gene promoter regions in target tissue cells, modulating tissue-specific gene expression patterns to support normal cellular function and counteract age-related decline.
Proposed targets include genes regulating prostate epithelial proliferation and differentiation, androgen receptor signalling sensitivity, and local immune function within prostatic and testicular tissue. Russian research groups have reported testagen-induced improvements in indices of urinary and sexual function in elderly men with age-related prostatic and testicular decline, and animal studies have suggested effects on testicular function markers and prostate gland histology.
As with all Khavinson bioregulators, the published efficacy evidence sits almost entirely within Russian gerontology research traditions and has not been replicated in independent Western randomised controlled trials. Importantly, testagen is not validated for the prevention or treatment of prostate cancer or benign prostatic hyperplasia, and its safety in men with hormone-sensitive cancers has not been established. Use should not displace evidence-based urology care, and users with prostate concerns should consult a urologist rather than relying on bioregulator protocols.
Thymosin Beta-4
Thymosin Beta-4 (Tβ4) is a 43-amino-acid peptide and the most abundant member of the beta-thymosin family. Despite its name (derived from its original isolation from thymus tissue), Tβ4 is expressed in virtually every nucleated cell in the body and is particularly concentrated in platelets, wound fluid, and developing tissues. TB-500 is the commercially available active fragment.
The primary molecular function is G-actin sequestration. Tβ4 binds globular actin (G-actin) monomers at a 1:1 stoichiometric ratio through a central actin-binding domain (LKKTET motif), maintaining a large intracellular pool of unpolymerized actin available for rapid mobilization. When cells need to migrate — as during wound healing, inflammation, or development — Tβ4 releases G-actin for polymerization into filamentous actin (F-actin) at the cell's leading edge. This dynamic actin cycling is the fundamental force-generating mechanism for cell migration.
Beyond actin regulation, Tβ4 has extensive signaling functions. It promotes angiogenesis by stimulating endothelial cell migration, tubule formation, and the expression of VEGF and angiopoietin-1. It reduces inflammation by modulating NF-κB signaling, decreasing production of TNF-α, IL-1β, and other pro-inflammatory mediators. In wound healing, Tβ4 upregulates laminin-5 production — a key component of the basement membrane that guides epithelial cell migration during wound re-epithelialization. It activates cardiac progenitor cells and promotes cardiomyocyte survival following ischemic injury, an effect that has generated significant interest for cardiac repair applications.
Tβ4 also promotes stem cell migration and differentiation through activation of the Akt cell survival pathway. It stimulates hair follicle stem cell migration and differentiation, which has been observed as increased hair growth in animal studies. The combination of cell migration, angiogenesis, anti-inflammation, stem cell activation, and extracellular matrix remodeling makes Tβ4 one of the most comprehensive endogenous healing molecules identified.
Risks & Safety
Testagen
Common
generally reported as well tolerated.
Serious
very limited Western clinical data; not validated for prostate cancer prevention or treatment, and any effect on hormone-sensitive tissues remains uncharacterised in rigorous trials.
Rare
allergic reactions. Should not replace evidence-based urology care.
Thymosin Beta-4
Common
injection site irritation, headache, nausea, temporary fatigue.
Serious
may promote existing tumors by stimulating new blood vessel formation and cell movement, no long-term data on effects on tissue remodeling.
Rare
allergic reactions, localized infection.
Full Profiles
Testagen →
A Khavinson tetrapeptide (Lys-Glu-Asp-Gly) developed in Russia as a tissue-specific bioregulator targeting prostate and testicular tissue. Promoted for supporting age-related decline in male reproductive and urinary function. Sits in the same Khavinson family as the other tissue-specific cytogens. Western clinical evidence is limited.
Thymosin Beta-4 →
The full-length 43-amino-acid peptide naturally produced by the thymus gland — the parent molecule from which TB-500 is derived. Plays a key role in cell movement, tissue repair, wound healing, and reducing inflammation throughout the body. The full-length form may offer broader healing benefits than the TB-500 fragment alone.